ArticlePharmacoEconomics2018

Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.

M Ruggeri et al.PubMed ↗Publisher ↗

No numbers read from the abstract.